纤连蛋白Ⅲ型结构域蛋白5对HepG2肝癌细胞体外转移活性的影响及其机制

肝脏 ›› 2023, Vol. 28 ›› Issue (8): 943-946.

纤连蛋白Ⅲ型结构域蛋白5对HepG2肝癌细胞体外转移活性的影响及其机制

袁庆功, 张焱, 李军辉, 杨文彬

710004 陕西西安交通大学第二附属医院普通外科

收稿日期:2022-10-22 出版日期:2023-08-31 发布日期:2023-09-21
通讯作者: 杨文彬

Effect of fibronectin type III domain containing 5 on the metastatic activity of HepG2 hepatoma cells in vitro and its mechanism

YUAN Qing-gong, ZHANG Yan, LI Jun-hui, YANG Wen-bin

Department of General Surgery, the Second Affiliated Hospital of Xi'an Jiaotong University, Shaanxi 710004, China

Received:2022-10-22 Online:2023-08-31 Published:2023-09-21
Contact: YANG Wen-bin

摘要/Abstract

摘要： 目的研究纤连蛋白Ⅲ型结构域蛋白5对肝细胞癌的影响以及调控机制。方法以不同浓度0、5、10和20 μmol纤连蛋白Ⅲ型结构域蛋白5处理HeP G2细胞,通过MTT实验、集落形成实验、Transwell实验、流式细胞术和细胞划痕实验分析纤连蛋白Ⅲ型结构域蛋白5对HepG2细胞的活性、侵袭和迁移能力以及凋亡率的影响。通过蛋白免疫印迹法分析纤连蛋白Ⅲ型结构域蛋白对Wnt/β-catenin通路的作用。结果 0、5、10和20 μmol的纤连蛋白Ⅲ型结构域蛋白5可以降低HepG2细胞的生长活性(92.86±0.32比79.32±0.17比50.11±0.56比29.29±0.96),抑制HepG2细胞集落形成(238.25±12.28比126.91±9.56比68.93±9.25比32.53±7.32),并且能够阻止HepG2细胞的发生侵袭以及迁移(87.13±2.18比66.23±2.16比46.23±3.27比22.56±5.12; 88.46±12.55比55.08±9.21比39.62±5.63比19.26±5.71),诱导HepG2细胞凋亡(1.46±0.23比5.08±0.11比9.66±0.23比13.27±1.01)。进一步研究发现,纤连蛋白Ⅲ型结构域蛋白5的这些作用可能与Wnt/β-catenin信号通路的抑制有关。结论纤连蛋白Ⅲ型结构域蛋白5能够抑制HepG2细胞的转移活性,并且纤连蛋白Ⅲ型结构域蛋白5的抑癌作用可能与Wnt/β-catenin途径有关。

关键词: 纤连蛋白Ⅲ型结构域蛋白5, HepG2, 转移活性, 肝细胞癌

Abstract: Objective To investigate the effect of FNDC5 on hepatocellular carcinoma (HCC) and its related mechanisms in order to propose new ideas for the treatment of HCC.Methods HepG2 cells were divided into four groups based on FNDC5 concentration (0, 5, 10 and 20 μM). The activity, invasion and migration of HepG2 cells,as well as apoptosis rate, were analyzed by MTT test, colony formation test, Transwell test, flow cytometry and cell scratch test. The impact of FNDC5 on the Wnt/β-catenin pathway was analyzed by Western blot.Results FNDC5 reduced the growth activity of HepG2 cells (92.86±0.32 vs 79.32±0.17 vs 50.11±0.56 vs 29.29±0.96), inhibited HepG2 cell colony formation (238.25±12.28 vs 126.91±9.56 vs 68.93±9.25 vs 32.53±7.32), and prevented the occurrence of HepG2 cell invasion and migration (87.13±2.18 vs 66.23±2.16 vs 46.23±3.27 vs 22.56±5.12; 88.46±12.55 vs 55.08±9.21 vs 39.62±5.63 vs 19.26±5.71).FNDC5 also induced apoptosis in HepG2 cells (1.46±0.23 vs 5.08±0.11 vs 9.66±0.23 vs 13.27±1.01).Conclusion HepG2 cell metastatic activity can be inhibited by FNDC5, and the anti-tumor effect of FNDC5 may be connected to the Wnt/β-catenin signal pathway.

Key words: fibronectin type III domain containing 5, HepG2, Transfer activity, Hepatocellular carcinoma

袁庆功, 张焱, 李军辉, 杨文彬. 纤连蛋白Ⅲ型结构域蛋白5对HepG2肝癌细胞体外转移活性的影响及其机制[J]. 肝脏, 2023, 28(8): 943-946.

YUAN Qing-gong, ZHANG Yan, LI Jun-hui, YANG Wen-bin. Effect of fibronectin type III domain containing 5 on the metastatic activity of HepG2 hepatoma cells in vitro and its mechanism[J]. Chinese Hepatolgy, 2023, 28(8): 943-946.

参考文献

[1] 孟金霞,卢喜玲,别文倩,等. 乙肝肝硬化并发原发性肝癌的相关危险因素分析. 实用癌症杂志,2022,37(5):777-779.
[2] 刘振宇,黄秀婷,田晓娟,等. Wnt/β-Catenin信号通路对氧化应激损伤促进食管癌细胞凋亡的调控研究. 广州医科大学学报,2019,47(5):1-4.
[3] Tejeda ME, Canto P, Tenorio-Torres A, et al. Increased FNDC5/IRISIN protein expression in breast cancer tissue is associated with obesity in postmenopausal women. J Clin Pathol, 2021, 15(2):2471-2476.
[4] Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol, 2019,16(10):589-604.
[5] Kulik L, El-serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology, 2019,156(2):477-491.
[6] Ma LA, Kim H, Desbordes C. Effects of biguanides on growth and glycolysis of bladder and colon cancer cells. Anticancer Res, 2018,38(9):5003-5011.
[7] Zhu T, Zhang W, Zhang Y, et al. Irisin/FNDC5 inhibits the epithelial-mesenchymal transition of epithelial ovarian cancer cells via the PI3K/Akt pathway. Arch Gynecol Obstet, 2022,306(3):841-850.
[8] Zhang Y, Li C, Hu C, et al. Lin28 enhances de novo fatty acid synthesis to promote cancer progression via SREBP-1. EMB O Rep, 2019, 20(10):e48115.
[9] Hao Q, Li T, Zhang X, et al. Expression and roles of fatty acid synthase in hepatocellular carcinoma. Oncol Rep, 2014,32(6):2471-2476.
[10] Wang X, Mao L, Li C, et al. The potential role of FNDC5/irisin in various liver diseases: awakening the sleeping beauties. Expert Rev Mol Med, 2022,2(4):16-23.
[11] Zhang Y, Wang X. Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol, 2020,13(1):165-173.
[12] Yu F, Yu C, Li F, et al. Wnt/β-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther, 2021,6(1):307-316.
[13] Liu J, Xiao Q, Xiao J, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther, 2022,7(1):3-11.
[14] Anthony CC, Robbins DJ, Ahmed Y, et al. Nuclear regulation of Wnt/β-Catenin signaling: it's a complex situation. Genes (Basel), 2020,11(8):886-897.

[1]	聂彬, 赵铁军, 张胜龙. 肝细胞癌伴微血管侵犯不同切缘方案下根治术的预后分析[J]. 肝脏, 2023, 28(8): 921-923.
[2]	徐嘉嫔, 邵春燕, 刘地发, 许亚春. 体素内不相干运动扩散加权成像对肝细胞癌微血管侵犯预测和TACE疗效的评估价值[J]. 肝脏, 2023, 28(8): 938-942.
[3]	王庆, 范芯铷, 汪慧. 重视晚期肝癌肝功能状态对免疫检查点抑制剂疗效的评估[J]. 肝脏, 2023, 28(7): 751-752.
[4]	黄倩, 李亚楠, 曾达武. ANLN、CYP2C9、HMMR在乙型肝炎病毒相关肝细胞癌中的表达及其对预后的影响[J]. 肝脏, 2023, 28(7): 775-780.
[5]	陈倩倩, 杨玥, 倪文婧, 芮法娟, 施军平, 李婕. 非酒精性脂肪性肝病相关肝细胞癌的防治策略研究进展[J]. 肝脏, 2023, 28(6): 639-643.
[6]	马伯恒, 王霞, 吴颖. 肉瘤样肝细胞癌血清生化指标、病理特征及手术疗效评估[J]. 肝脏, 2023, 28(6): 676-679.
[7]	靳志恩, 徐攀, 袁宏伟, 徐敬江. HCV感染者接受直接抗病毒药物治疗肝细胞癌风险变化[J]. 肝脏, 2023, 28(6): 680-682.
[8]	黄梦, 钱晓寒, 杨丽华. 环状RNA应用于肝细胞癌无创早期诊断的研究进展[J]. 肝脏, 2023, 28(6): 720-724.
[9]	肖滢, 吴治念, 王亚东. 肝素非抗凝作用在肝病应用中的研究进展[J]. 肝脏, 2023, 28(6): 730-733.
[10]	武超玉. 以发热为主要表现的肝脏原发性平滑肌肉瘤1例[J]. 肝脏, 2023, 28(6): 741-742.
[11]	黄孙桦, 刘建东, 黄罡. 肝细胞癌免疫治疗生物标志物的研究进展[J]. 肝脏, 2023, 28(5): 510-512.
[12]	陈克敏. 成像生物标记物预测肝细胞癌免疫治疗反应的研究进展[J]. 肝脏, 2023, 28(5): 513-514.
[13]	邓霖霖, 石清兰, 韦华柱, 莫展进, 黄祖鸿. 乙型肝炎病毒相关肝细胞癌高危因素分析[J]. 肝脏, 2023, 28(5): 614-617.
[14]	范芯铷, 刘铭佳, 王庆, 汪慧. 原发性肝癌的发病机制及治疗进展[J]. 肝脏, 2023, 28(4): 391-392.
[15]	钱厚龙, 李阳, 朱翔, 路逵. 卡瑞利珠单抗联合仑伐替尼治疗不可切除肝细胞癌的疗效和安全性[J]. 肝脏, 2023, 28(4): 452-456.